{"id":41530,"date":"2025-09-16T15:40:59","date_gmt":"2025-09-16T07:40:59","guid":{"rendered":"https:\/\/flcube.com\/?p=41530"},"modified":"2025-09-16T15:41:00","modified_gmt":"2025-09-16T07:41:00","slug":"biocytogen-licenses-renmice-antibody-to-tubulis-boosting-adc-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=41530","title":{"rendered":"Biocytogen Licenses RenMice Antibody to Tubulis, Boosting ADC Development"},"content":{"rendered":"\n<p><strong>Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/2315:HKG\">HKG: 2315<\/a>)<\/strong> announced today that it has entered into a definitive antibody licensing agreement with <strong>Tubulis<\/strong>, a leading developer of antibody\u2011drug conjugates (ADCs). The deal will enable Tubulis to harness Biocytogen\u2019s proprietary <strong>RenMice<\/strong> fully human antibody platform to accelerate the development and commercialization of its next\u2011generation ADC portfolio.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-deal-highlights\">Deal Highlights<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Key Feature<\/th><th>Description<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensing Basis<\/strong><\/td><td>Biocytogen\u2019s RenMice antibody, developed via its own discovery platform, will be licensed to Tubulis for use in ADCs.<\/td><\/tr><tr><td><strong>Strategic Fit<\/strong><\/td><td>The collaboration builds on a prior research partnership and option agreement focused on antibody molecules for ADCs.<\/td><\/tr><tr><td><strong>Financial Terms<\/strong><\/td><td>Biocytogen receives an upfront payment, plus development, regulatory, and commercial milestone payments, and will earn single\u2011digit percentage royalties on net sales.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-technology-edge\">Technology Edge<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>RenMice Platform<\/strong> \u2013 Provides antibodies with <strong>high affinity<\/strong>, <strong>low immunogenicity<\/strong>, and robust development potential.<\/li>\n\n\n\n<li><strong>Tubulis\u2019 Complementary Assets<\/strong> \u2013 Proprietary linker and payload technologies will be combined with the RenMice antibody to create highly potent, tumor\u2011selective ADCs.<\/li>\n\n\n\n<li><strong>Unmet Clinical Need<\/strong> \u2013 The partnership targets cancer indications where current ADC options are limited, positioning the new products for rapid differentiation.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-path-forward\">Path Forward<\/h3>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Preclinical Development<\/strong> \u2013 Joint teams will integrate the RenMice antibody into Tubulis\u2019 linker\u2011payload format and conduct target\u2011specific efficacy studies.<\/li>\n\n\n\n<li><strong>Clinical Translation<\/strong> \u2013 Upon successful preclinical milestones, the ADC candidates will progress to Phase\u202fI clinical trials, leveraging Tubulis\u2019 established clinical development pipeline.<\/li>\n\n\n\n<li><strong>Commercial Strategy<\/strong> \u2013 The agreement outlines clear commercialization pathways, with Biocytogen actively involved in strategic decisions and benefiting from milestone and royalty upside.<\/li>\n<\/ol>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-market-impact\">Market Impact<\/h3>\n\n\n\n<p>The collaboration represents a significant convergence of discovery\u2011speed and delivery\u2011speed. By marrying Biocytogen\u2019s high\u2011quality antibody scaffold with Tubulis\u2019 cutting\u2011edge ADC chemistry, the alliance aims to deliver a new class of anticancer agents that offer superior potency, reduced toxicity, and improved dosing schedules. This partnership is expected to strengthen both companies\u2019 positions in the competitive ADC market and accelerate the delivery of innovative therapies to patients worldwide.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) announced today that it has entered into a&#8230;<\/p>\n","protected":false},"author":1,"featured_media":41532,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[35,1519,1214,4355],"class_list":["post-41530","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-adc-xdc","tag-biocytogen-pharmaceuticals","tag-hkg-2315","tag-tubulis"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Biocytogen Licenses RenMice Antibody to Tubulis, Boosting ADC Development - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) announced today that it has entered into a definitive antibody licensing agreement with Tubulis, a leading developer of antibody\u2011drug conjugates (ADCs). The deal will enable Tubulis to harness Biocytogen\u2019s proprietary RenMice fully human antibody platform to accelerate the development and commercialization of its next\u2011generation ADC portfolio.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=41530\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biocytogen Licenses RenMice Antibody to Tubulis, Boosting ADC Development\" \/>\n<meta property=\"og:description\" content=\"Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) announced today that it has entered into a definitive antibody licensing agreement with Tubulis, a leading developer of antibody\u2011drug conjugates (ADCs). The deal will enable Tubulis to harness Biocytogen\u2019s proprietary RenMice fully human antibody platform to accelerate the development and commercialization of its next\u2011generation ADC portfolio.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=41530\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-16T07:40:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-16T07:41:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1602.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41530#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41530\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Biocytogen Licenses RenMice Antibody to Tubulis, Boosting ADC Development\",\"datePublished\":\"2025-09-16T07:40:59+00:00\",\"dateModified\":\"2025-09-16T07:41:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41530\"},\"wordCount\":334,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41530#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1602.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"Biocytogen Pharmaceuticals\",\"HKG: 2315\",\"Tubulis\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41530#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41530\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=41530\",\"name\":\"Biocytogen Licenses RenMice Antibody to Tubulis, Boosting ADC Development - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41530#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41530#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1602.webp\",\"datePublished\":\"2025-09-16T07:40:59+00:00\",\"dateModified\":\"2025-09-16T07:41:00+00:00\",\"description\":\"Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) announced today that it has entered into a definitive antibody licensing agreement with Tubulis, a leading developer of antibody\u2011drug conjugates (ADCs). The deal will enable Tubulis to harness Biocytogen\u2019s proprietary RenMice fully human antibody platform to accelerate the development and commercialization of its next\u2011generation ADC portfolio.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41530#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41530\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41530#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1602.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1602.webp\",\"width\":1080,\"height\":608,\"caption\":\"Biocytogen Licenses RenMice Antibody to Tubulis, Boosting ADC Development\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41530#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biocytogen Licenses RenMice Antibody to Tubulis, Boosting ADC Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Biocytogen Licenses RenMice Antibody to Tubulis, Boosting ADC Development - Insight, China&#039;s Pharmaceutical Industry","description":"Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) announced today that it has entered into a definitive antibody licensing agreement with Tubulis, a leading developer of antibody\u2011drug conjugates (ADCs). The deal will enable Tubulis to harness Biocytogen\u2019s proprietary RenMice fully human antibody platform to accelerate the development and commercialization of its next\u2011generation ADC portfolio.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=41530","og_locale":"en_US","og_type":"article","og_title":"Biocytogen Licenses RenMice Antibody to Tubulis, Boosting ADC Development","og_description":"Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) announced today that it has entered into a definitive antibody licensing agreement with Tubulis, a leading developer of antibody\u2011drug conjugates (ADCs). The deal will enable Tubulis to harness Biocytogen\u2019s proprietary RenMice fully human antibody platform to accelerate the development and commercialization of its next\u2011generation ADC portfolio.","og_url":"https:\/\/flcube.com\/?p=41530","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-16T07:40:59+00:00","article_modified_time":"2025-09-16T07:41:00+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1602.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=41530#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=41530"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Biocytogen Licenses RenMice Antibody to Tubulis, Boosting ADC Development","datePublished":"2025-09-16T07:40:59+00:00","dateModified":"2025-09-16T07:41:00+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=41530"},"wordCount":334,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=41530#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1602.webp","keywords":["ADC \/ XDC","Biocytogen Pharmaceuticals","HKG: 2315","Tubulis"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=41530#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=41530","url":"https:\/\/flcube.com\/?p=41530","name":"Biocytogen Licenses RenMice Antibody to Tubulis, Boosting ADC Development - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=41530#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=41530#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1602.webp","datePublished":"2025-09-16T07:40:59+00:00","dateModified":"2025-09-16T07:41:00+00:00","description":"Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) announced today that it has entered into a definitive antibody licensing agreement with Tubulis, a leading developer of antibody\u2011drug conjugates (ADCs). The deal will enable Tubulis to harness Biocytogen\u2019s proprietary RenMice fully human antibody platform to accelerate the development and commercialization of its next\u2011generation ADC portfolio.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=41530#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=41530"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=41530#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1602.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1602.webp","width":1080,"height":608,"caption":"Biocytogen Licenses RenMice Antibody to Tubulis, Boosting ADC Development"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=41530#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Biocytogen Licenses RenMice Antibody to Tubulis, Boosting ADC Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1602.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41530","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=41530"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41530\/revisions"}],"predecessor-version":[{"id":41533,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41530\/revisions\/41533"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/41532"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=41530"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=41530"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=41530"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}